These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38914856)

  • 1. Falls and Fractures among Nursing Home Residents Treated with Pimavanserin versus Other Atypical Antipsychotics: Analysis of Medicare Beneficiaries with Parkinson's Disease Psychosis.
    Rajagopalan K; Rashid N; Gopal D; Doshi D
    Drugs Real World Outcomes; 2024 Sep; 11(3):441-449. PubMed ID: 38914856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Healthcare resource utilization among nursing home residents with Parkinson's disease psychosis: an analysis of Medicare beneficiaries treated with pimavanserin or other-atypical antipsychotics.
    Rajagopalan K; Rashid N; Gopal D; Doshi D
    J Comp Eff Res; 2024 Jul; 13(7):e240038. PubMed ID: 38850129
    [No Abstract]   [Full Text] [Related]  

  • 3. Risk of long-term care admissions among Medicare beneficiaries treated with pimavanserin or quetiapine for Parkinson's disease psychosis in USA: a retrospective administrative claims database analysis.
    Rajagopalan K; Rashid N; Doshi D
    J Comp Eff Res; 2024 Jan; 13(1):e230114. PubMed ID: 38099518
    [No Abstract]   [Full Text] [Related]  

  • 4. Health care resource utilization patterns among patients with Parkinson's disease psychosis: analysis of Medicare beneficiaries treated with pimavanserin or other-atypical antipsychotics.
    Rajagopalan K; Rashid N; Kumar S; Doshi D
    J Med Econ; 2023; 26(1):34-42. PubMed ID: 36444507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patients treated with pimavanserin or quetiapine for Parkinson's disease psychosis: analysis of health resource utilization patterns among Medicare beneficiaries.
    Rajagopalan K; Rashid N; Doshi D
    J Med Econ; 2023; 26(1):769-776. PubMed ID: 37272069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of Medicare Patients Treated with Pimavanserin versus Other Atypical Antipsychotics: A Cost-Offset Model Evaluating Skilled Nursing Facility Stays and Long-Term Care Admissions in Parkinson's Disease Psychosis.
    Rajagopalan K; Rashid N; Yakkala V; Doshi D
    Clinicoecon Outcomes Res; 2024; 16():149-159. PubMed ID: 38495124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mortality in Patients with Parkinson's Disease-Related Psychosis Treated with Pimavanserin Compared with Other Atypical Antipsychotics: A Cohort Study.
    Layton JB; Forns J; McQuay LJ; Danysh HE; Dempsey C; Anthony MS; Turner ME
    Drug Saf; 2023 Feb; 46(2):195-208. PubMed ID: 36517664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Falls and Fractures in Patients with Parkinson's Disease-Related Psychosis Treated with Pimavanserin vs Atypical Antipsychotics: A Cohort Study.
    Layton JB; Forns J; Turner ME; Dempsey C; Bartsch JL; Anthony MS; Danysh HE; Ritchey ME; Demos G
    Drugs Real World Outcomes; 2022 Mar; 9(1):9-22. PubMed ID: 34718963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Outcomes of Commonly Used Off-Label Atypical Antipsychotics in the Treatment of Dementia-Related Psychosis: A Network Meta-analysis.
    Yunusa I; Rashid N; Demos GN; Mahadik BS; Abler VC; Rajagopalan K
    Adv Ther; 2022 May; 39(5):1993-2008. PubMed ID: 35247186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Efficacy, Safety, and Acceptability of Pimavanserin and Other Atypical Antipsychotics for Parkinson's Disease Psychosis: Systematic Review and Network Meta-Analysis.
    Yunusa I; Rashid N; Seyedin R; Paratane D; Rajagopalan K
    J Geriatr Psychiatry Neurol; 2023 Sep; 36(5):417-432. PubMed ID: 36720473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incremental health care resource utilization and costs associated among patients with Parkinson's disease psychosis and incident dementia: An analysis of medicare beneficiaries.
    Rajagopalan K; Rashid N; Gopal D; Doshi D
    Int J Geriatr Psychiatry; 2023 Nov; 38(11):e6017. PubMed ID: 37936540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mortality Among Parkinson's Disease Patients Treated With Pimavanserin or Atypical Antipsychotics: An Observational Study in Medicare Beneficiaries.
    Mosholder AD; Ma Y; Akhtar S; Podskalny GD; Feng Y; Lyu H; Liao J; Wei Y; Wernecke M; Leishear K; Nelson LM; MaCurdy TE; Kelman JA; Graham DJ
    Am J Psychiatry; 2022 Aug; 179(8):553-561. PubMed ID: 35702829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative treatment patterns, resource utilization, and costs in stimulant-treated children with ADHD who require subsequent pharmacotherapy with atypical antipsychotics versus non-antipsychotics.
    Sikirica V; Pliszka SR; Betts KA; Hodgkins P; Samuelson T; Xie J; Erder H; Dammerman R; Robertson B; Wu EQ
    J Manag Care Pharm; 2012; 18(9):676-89. PubMed ID: 23206211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective analyses evaluating the mortality risk associated with pimavanserin or other atypical antipsychotics in patients with Parkinson disease psychosis.
    Isaacson SH; Pahwa R; Pagan F; Abler V; Truong D
    Clin Park Relat Disord; 2024; 10():100256. PubMed ID: 38770047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Pimavanserin Treatment-Continuity on Discharge From Long-term Care: Assessing the Quality of Antipsychotic Medication Review.
    Rajagopalan K; May D; Worz C; Hernandez S; Doshi D
    Sr Care Pharm; 2022 Oct; 37(10):510-522. PubMed ID: 36171673
    [No Abstract]   [Full Text] [Related]  

  • 16. Risk of pneumonia associated with atypical antipsychotic use in nursing home residents with Parkinson's disease.
    Chekani F; Holmes HM; Johnson ML; Chen H; Sherer JT; Aparasu RR
    J Psychiatr Res; 2019 Oct; 117():116-121. PubMed ID: 31377483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clearing the Fog: A Review of Antipsychotics for Parkinson's-Related Hallucinations: A Focus on Pimavanserin, Quetiapine and Clozapine.
    Abdul-Rahman T; Herrera-Calderón RE; Aderinto N; Kundu M; Wireko AA; Adebusoye FT; Ekerin O; Lawal L; Mykolaivna NI; Alexiou A; Almashjary MN; Perveen A; Ashraf GM
    J Integr Neurosci; 2024 Apr; 23(4):80. PubMed ID: 38682215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atypical antipsychotics for psychosis in adolescents.
    Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
    Cochrane Database Syst Rev; 2013 Oct; 2013(10):CD009582. PubMed ID: 24129841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sulfonylureas and risk of falls and fractures among nursing home residents with type 2 diabetes mellitus.
    Lapane KL; Jesdale BM; Dubé CE; Pimentel CB; Rajpathak SN
    Diabetes Res Clin Pract; 2015 Aug; 109(2):411-9. PubMed ID: 26008723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of falls and fractures in older adults using atypical antipsychotic agents: a propensity score-adjusted, retrospective cohort study.
    Chatterjee S; Chen H; Johnson ML; Aparasu RR
    Am J Geriatr Pharmacother; 2012 Apr; 10(2):83-94. PubMed ID: 22306198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.